Q-omics provides the consensus-scored ZNF684 profile across patient tissues and cancer cell-line models. ZNF684 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZNF684 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ZNF684 RNA expression shows 20,688 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where ZNF684 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF684 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF684 survival associations across molecular data types. ZNF684 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF684 RNA expression–survival associations across cancer types. High ZNF684 expression shows unfavorable associations in LGG and UVM, but favorable associations in LUAD, KIRC, KIRP and HNSC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZNF684 RNA expression.
This table summarizes ZNF684 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF684. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF684 shows lower tumor expression in KIRC, THCA, KIRP and COAD and higher tumor expression in HNSC and BLCA. The KIRC box plot shows higher ZNF684 RNA expression in normal versus tumor tissue (log2 FC = −0.835, t-test p < 0.001).
This table shows molecular features associated with ZNF684 in patient tissues and cancer cell lines. In patient samples, ZNF684 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF684 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
